当前位置: X-MOL 学术BMC Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
BMC Cancer ( IF 3.4 ) Pub Date : 2020-06-30 , DOI: 10.1186/s12885-020-07104-9
Sivan Shamai 1, 2 , Zach Rozenbaum 2, 3 , Ofer Merimsky 1, 2 , Matthew Derakhshesh 2 , Yonatan Moshkovits 2 , Joshua Arnold 2 , Yan Topilsky 2, 3 , Yaron Arbel 2, 3 , Michal Laufer-Perl 2, 3
Affiliation  

Chemotherapy induced cardio-toxicity has been recognized as a serious side effect since the first introduction to anthracyclines (ANT). Cardio-toxicity among patients with breast cancer is well studied but the impact on patients with sarcoma is limited, even though they are exposed to higher ANT doses. The commonly used term for cardio-toxicity is cancer therapeutics related cardiac dysfunction (CTRCD), defined as a left ventricular ejection fraction (LVEF) reduction of > 10%, to a value below 53%. The aim of our study was to estimate the prevalence of CTRCD in patients diagnosed with sarcoma and to describe the baseline risk factors and echocardiography parameters among that population. Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), enrolling all patients evaluated in the cardio-oncology clinic at our institution. The registry was approved by the local ethics committee and is registered in clinicaltrials.gov (Identifier: NCT02818517). All sarcoma patients were enrolled and divided into two groups - CTRCD group vs. non-CTRCD group. Among 43 consecutive patients, 6 (14%) developed CTRCD. Baseline cardiac risk factors were more frequent among the non-CTRCD group. Elevated left ventricular end systolic diameter and reduced Global Longitudinal Strain were observed among the CTRCD group. During follow-up, 2 (33%) patients died in the CTRCD group vs. 3 (8.1%) patients in the non-CTRCD group. CTRCD is an important concern among patients with sarcoma, regardless of baseline risk factors. Echocardiography parameters may provide an early diagnosis of cardio-toxicity.

中文翻译:

肉瘤患者的心脏毒性:心血管肿瘤登记。

自从蒽环类药物(ANT)首次引入以来,化学疗法诱导的心脏毒性已被认为是严重的副作用。对乳腺癌患者的心脏毒性进行了很好的研究,但即使肉瘤患者接受较高的ANT剂量,其对肉瘤患者的影响也很有限。心脏毒性的常用术语是与癌症治疗相关的心脏功能障碍(CTRCD),定义为左心室射血分数(LVEF)降低> 10%,降至53%以下。我们研究的目的是评估在诊断为肉瘤的患者中CTRCD的患病率,并描述该人群中的基线危险因素和超声心动图参数。数据是作为以色列心脏肿瘤注册中心(ICOR)的一部分收集的,所有在我们机构的心脏肿瘤诊所接受评估的患者均入组。该注册表已获得当地伦理委员会的批准,并已在Clinicaltrials.gov中注册(标识:NCT02818517)。所有肉瘤患者均入选,分为两组-CTRCD组与非CTRCD组。在连续的43位患者中,有6位(14%)发展为CTRCD。非CTRCD组中基线心脏危险因素更为常见。在CTRCD组中,观察到左室收缩末期直径升高和全球纵向应变降低。在随访期间,CTRCD组死亡2例(33%),非CTRCD组死亡3例(8.1%)。无论基线危险因素如何,CTRCD都是肉瘤患者中的重要问题。超声心动图参数可以提供心脏毒性的早期诊断。gov(标识符:NCT02818517)。所有肉瘤患者均入选,分为两组-CTRCD组与非CTRCD组。在43位连续患者中,有6位(14%)发展为CTRCD。非CTRCD组中基线心脏危险因素更为常见。在CTRCD组中,观察到左室收缩末期直径升高和全球纵向应变降低。在随访期间,CTRCD组死亡2例(33%),非CTRCD组死亡3例(8.1%)。无论基线危险因素如何,CTRCD都是肉瘤患者中的重要问题。超声心动图参数可以提供心脏毒性的早期诊断。gov(标识符:NCT02818517)。所有肉瘤患者均入选,分为两组-CTRCD组与非CTRCD组。在43位连续患者中,有6位(14%)发展为CTRCD。非CTRCD组中基线心脏危险因素更为常见。在CTRCD组中,观察到左室收缩末期直径升高和全球纵向应变降低。在随访期间,CTRCD组死亡2例(33%),非CTRCD组死亡3例(8.1%)。无论基线危险因素如何,CTRCD都是肉瘤患者中的重要问题。超声心动图参数可以提供心脏毒性的早期诊断。非CTRCD组中基线心脏危险因素更为常见。在CTRCD组中,观察到左室收缩末期直径升高和全球纵向应变降低。在随访期间,CTRCD组死亡2例(33%),非CTRCD组死亡3例(8.1%)。无论基线危险因素如何,CTRCD都是肉瘤患者中的重要问题。超声心动图参数可以提供心脏毒性的早期诊断。非CTRCD组中基线心脏危险因素更为常见。在CTRCD组中,观察到左室收缩末期直径升高和全球纵向应变降低。在随访期间,CTRCD组死亡2例(33%),非CTRCD组死亡3例(8.1%)。无论基线危险因素如何,CTRCD都是肉瘤患者中的重要问题。超声心动图参数可以提供心脏毒性的早期诊断。
更新日期:2020-06-30
down
wechat
bug